Dr. Thomas Karikari, a professor of psychiatry at the University of Pittsburgh and co-author of the study on the new blood test for detecting Alzheimer’s disease, believes that the test has the potential to improve the design of clinical trials for Alzheimer’s treatments. He stated that the blood test is more cost-effective, safer, and easier to administer compared to current methods, and it can enhance clinical confidence in diagnosing Alzheimer’s and selecting participants for clinical trials and disease monitoring. However, before the test becomes widely available, the research team needs to confirm that it is effective for a diverse range of patients, including individuals from different ethnic backgrounds.
Image Source - Twitter
